Search

Your search keyword '"PISCAGLIA, FABIO"' showing total 38 results
Start Over Author "PISCAGLIA, FABIO" Publisher lippincott williams & wilkins
38 results on '"PISCAGLIA, FABIO"'

2. Contrast-enhanced ultrasound liver imaging reporting and data system: clinical validation in a prospective multinational study in North America and Europe.

Author

Lyshchik, Andrej, Wessner, Corinne E., Bradigan, Kristen, Eisenbrey, John R., Forsberg, Flemming, Misung Yi, Keith, Scott W., Yuko Kono, Wilson, Stephanie R., Medellin, Alexandra, Rodgers, Shuchi K., Planz, Virginia, Kamaya, Aya, Finch, Lisa, Fetzer, David T., Berzigotti, Annalisa, Sidhu, Paul S., and Piscaglia, Fabio

Published
2024
Full Text
View/download PDF

4. Serum Albumin Is Inversely Associated With Portal Vein Thrombosis in Cirrhosis.

Author

Basili, Stefania, Carnevale, Roberto, Nocella, Cristina, Bartimoccia, Simona, Raparelli, Valeria, Talerico, Giovanni, Stefanini, Lucia, Romiti, Giulio F., Perticone, Francesco, Corazza, Gino R., Piscaglia, Fabio, Pietrangelo, Antonello, and Violi, Francesco

Subjects
CIRRHOSIS of the liver, SERUM albumin, PORTAL vein diseases
Abstract

We analyzed whether serum albumin is independently associated with portal vein thrombosis (PVT) in liver cirrhosis (LC) and if a biologic plausibility exists. This study was divided into three parts. In part 1 (retrospective analysis), 753 consecutive patients with LC with ultrasound‐detected PVT were retrospectively analyzed. In part 2, 112 patients with LC and 56 matched controls were entered in the cross‐sectional study. In part 3, 5 patients with cirrhosis were entered in the in vivo study and 4 healthy subjects (HSs) were entered in the in vitro study to explore if albumin may affect platelet activation by modulating oxidative stress. In the 753 patients with LC, the prevalence of PVT was 16.7%; logistic analysis showed that only age (odds ratio [OR], 1.024; P = 0.012) and serum albumin (OR, −0.422; P = 0.0001) significantly predicted patients with PVT. Analyzing the 112 patients with LC and controls, soluble clusters of differentiation (CD)40‐ligand (P = 0.0238), soluble Nox2‐derived peptide (sNox2‐dp; P < 0.0001), and urinary excretion of isoprostanes (P = 0.0078) were higher in patients with LC. In LC, albumin was correlated with sCD40L (Spearman's rank correlation coefficient [rs], −0.33; P < 0.001), sNox2‐dp (rs, −0.57; P < 0.0001), and urinary excretion of isoprostanes (rs, −0.48; P < 0.0001) levels. The in vivo study showed a progressive decrease in platelet aggregation, sNox2‐dp, and urinary 8‐iso prostaglandin F2α‐III formation 2 hours and 3 days after albumin infusion. Finally, platelet aggregation, sNox2‐dp, and isoprostane formation significantly decreased in platelets from HSs incubated with scalar concentrations of albumin. Conclusion: Low serum albumin in LC is associated with PVT, suggesting that albumin could be a modulator of the hemostatic system through interference with mechanisms regulating platelet activation. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

6. Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice.

Author

Giannini, Edoardo Giovanni, Bucci, Laura, Garuti, Francesca, Brunacci, Matteo, Lenzi, Barbara, Valente, Matteo, Caturelli, Eugenio, Cabibbo, Giuseppe, Piscaglia, Fabio, Virdone, Roberto, Felder, Martina, Ciccarese, Francesca, Foschi, Francesco Giuseppe, Sacco, Rodolfo, Svegliati Baroni, Gianluca, Farinati, Fabio, Rapaccini, Gian Lodovico, Olivani, Andrea, Gasbarrini, Antonio, and Di Marco, Maria

Published
2018
Full Text
View/download PDF

9. Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor.

Author

Vitale, Alessandro, Farinati, Fabio, Burra, Patrizia, Trevisani, Franco, Giannini, Edoardo G., Ciccarese, Francesca, Piscaglia, Fabio, Rapaccini, Gian Lodovico, Di Marco, Mariella, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Cabibbo, Giuseppe, Felder, Martina, Sacco, Rodolfo, Morisco, Filomena, Missale, Gabriele, Foschi, Francesco Giuseppe, Gasbarrini, Antonio, and Svegliati Baroni, Gianluca

Published
2015
Full Text
View/download PDF

11. Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection.

Author

Sagrini, Elisabetta, Ardoino, Ilaria, Marano, Giuseppe, Gianstefani, Alice, Orlandini, Alessandra, Sebastiani, Giada, Donati, Gabriele, Cucchetti, Alessandro, Pelosi, Guido, Ferrari, Carlo, Alberti, Alfredo, Biganzoli, Ella, Piscaglia, Fabio, and Bolondi, Luigi

Published
2013
Full Text
View/download PDF

29. Correction: Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma.

Author

Giannini, Edoardo G., Moscatelli, Alessandro, Pellegatta, Gaia, Vitale, Alessandro, Farinati, Fabio, Ciccarese, Francesca, Piscaglia, Fabio, Rapaccini, Gian Lodovico, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Cabibbo, Giuseppe, Felder, Martina, Sacco, Rodolfo, Morisco, Filomena, Missale, Gabriele, Foschi, Francesco Giuseppe, Gasbarrini, Antonio, and Baroni, Gianluca Svegliati

Published
2018
Full Text
View/download PDF

37. Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential Treatments.

Author

Tovoli F, Pallotta DP, Sansone V, Iavarone M, De Giorgio M, Ielasi L, Di Costanzo GG, Giuffrida P, Sacco R, Pressiani T, Di Donato MF, Trevisani F, Fagiuoli S, Piscaglia F, and Granito A

Subjects
Humans, Sorafenib therapeutic use, Retrospective Studies, Prospective Studies, Neoplasm Recurrence, Local epidemiology, Carcinoma, Hepatocellular drug therapy, Carcinoma, Hepatocellular surgery, Liver Transplantation adverse effects, Liver Neoplasms drug therapy, Liver Neoplasms surgery
Abstract

Background: Sorafenib and other tyrosine kinase inhibitors are the current standard of care for hepatocellular carcinoma (HCC) recurring after liver transplantation (LT). Sorafenib is sometimes regarded as a scarcely effective treatment in this setting because of some studies showing a short overall survival (OS) indirectly compared with historical series of nontransplanted patients. Additional data from multicenter prospective studies are needed before drawing definite conclusions., Methods: Retrospective analyses of a large prospective multicenter dataset of sorafenib-treated HCC patients to report the characteristics and outcomes of LT recipients (n = 81)., Results: At the baseline, LT patients had key prognostic features (high prevalence of metastatic disease, and low prevalence of macrovascular invasion, α-fetoprotein >400 ng/mL, ALBI grade >1, performance status >0) that differentiated them from the typical populations of non-LT patient reported in clinical trials and observational studies. Moreover, a relevant proportion of LT patients received concurrent locoregional (12.3%) and postprogression systemic treatments (34.2%), resulting in a median OS of 18.7 mo., Conclusions: Multimodal and sequential treatments are relatively frequent in post-LT HCC patients and contribute to a remarkable OS, together with favorable baseline characteristics. Despite the impossibility of matching with non-LT patients, our results indirectly suggest that the metastatic nature of post-LT recurrence and concurrent antirejection regimens should not discourage systemic treatments., Competing Interests: F.T. has served as a consultant for Bayer, Ipsen, and Eisai and an advisory board member for Laforce. M.I.: speaking/teaching, consultant, and the advisory board for Bayer, Gilead Sciences, BMS, Janssen, Ipsen, MSD, BTG-Boston Scientific, AbbVie, Guerbet, and EISAI. M.D.G. received honoraria for serving on advisory boards for Eisai and Bayer. F.T. is an advisor and a consultant for Bayer and an advisory board member for Sirtex, Alfasigma, and Bristol-Myers Squibb. F.P. is a consultant for AstraZeneca, Bayer AG, EISAI, GE, and Tiziana Life Sciences; Speaker bureau honoraria: Bayer AG, Bracco, EISAI, and Laforce; research contract with Esaote. A.G. has served as a consultant for Bayer. The other authors declare no conflicts of interest., (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results